Kura Oncology Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 142

Employees

  • Stock Symbol
  • KURA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $19.77
  • (As of Tuesday Closing)

Kura Oncology General Information

Description

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Contact Information

Formerly Known As
Zeta Acquisition Corp Iii
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 12730 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kura Oncology Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$19.77 $20.69 $7.41 - $24.17 $1.51B 76.2M 707K -$2.17

Kura Oncology Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,217,244 632,864 424,764 395,689
Revenue 0 0 0 0
EBITDA (182,813) (164,955) (139,065) (130,658)
Net Income (168,087) (152,631) (135,840) (130,466)
Total Assets 553,908 448,935 456,306 534,051
Total Debt 16,970 17,200 14,024 6,875
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kura Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.

Request a free trial

Kura Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics
Biotechnology
San Diego, CA
142 As of 2023
00000
000000000 00000

000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillu
0000 000000000
Waltham, MA
000 As of 0000
00000
00000000 00000

000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000000000000
Andover, MA
00 As of 0000
00000
000000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kura Oncology Competitors (72)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Syndax Formerly VC-backed Waltham, MA 000 00000 00000000 00000
Oncorus Formerly VC-backed Andover, MA 00 00000 000000000000 00000
Ikena Oncology Formerly VC-backed Boston, MA 00 00000 00000000 00000
Sagimet Biosciences Formerly VC-backed San Mateo, CA 00 00000 00000000 00000
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland 000 00.000 00000000 00.000
You’re viewing 5 of 72 competitors. Get the full list »

Kura Oncology Patents

Kura Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240024301-A1 Methods of treating head and neck squamous cell carcinoma Pending 08-Apr-2022 00000000000
US-20230322711-A1 Macrocyclic compounds and compositions, and methods of preparing and using the same Pending 02-Dec-2021 0000000000
AU-2022399572-A1 Macrocyclic compounds having farnesyltransferase inhibitory activity Pending 30-Nov-2021 0000000000
CA-3234276-A1 Macrocyclic compounds having farnesyltransferase inhibitory activity Pending 30-Nov-2021 0000000000
EP-4232020-A1 Treatment of hematological malignancies with inhibitors of menin Pending 21-Oct-2020 A61K31/519
To view Kura Oncology’s complete patent history, request access »

Kura Oncology Executive Team (21)

Name Title Board Seat Contact Info
Troy Wilson Ph.D Co-founder, President, Chief Executive Officer & Chairman
Kathleen Ford Chief Operating Officer, Operations
Thomas Doyle Chief Accounting Officer, Accounting & Senior Vice President
Teresa Bair JD Secretary, Administration & Chief Legal Officer, Legal
Maria Palmiano Director, Finance
You’re viewing 5 of 21 executive team members. Get the full list »

Kura Oncology Board Members (8)

Name Representing Role Since
Carol Schafer Kura Oncology Board Member 000 0000
Diane Parks Self Board Member 000 0000
Faheem Hasnain Self Board Member 000 0000
Mary Szela Self Board Member 000 0000
Steven Stein MD Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Kura Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kura Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.

Request a free trial

Kura Oncology Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Zeta Acquisition 06-Mar-2015 0000000000 Holding Companies
To view Kura Oncology’s complete acquisitions history, request access »

Kura Oncology ESG

Risk Overview

Risk Rating

Updated March, 01, 2024

24.56 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Kura Oncology’s complete esg history, request access »

Kura Oncology FAQs

  • When was Kura Oncology founded?

    Kura Oncology was founded in 2014.

  • Who is the founder of Kura Oncology?

    Troy Wilson Ph.D is the founder of Kura Oncology.

  • Who is the CEO of Kura Oncology?

    Troy Wilson Ph.D is the CEO of Kura Oncology.

  • Where is Kura Oncology headquartered?

    Kura Oncology is headquartered in San Diego, CA.

  • What is the size of Kura Oncology?

    Kura Oncology has 142 total employees.

  • What industry is Kura Oncology in?

    Kura Oncology’s primary industry is Biotechnology.

  • Is Kura Oncology a private or public company?

    Kura Oncology is a Public company.

  • What is Kura Oncology’s stock symbol?

    The ticker symbol for Kura Oncology is KURA.

  • What is the current stock price of Kura Oncology?

    As of 18-Jun-2024 the stock price of Kura Oncology is $19.77.

  • What is the current market cap of Kura Oncology?

    The current market capitalization of Kura Oncology is $1.51B.

  • Who are Kura Oncology’s competitors?

    Syndax, Oncorus, Ikena Oncology, Sagimet Biosciences, and ADC Therapeutics are some of the 72 competitors of Kura Oncology.

  • What is Kura Oncology’s annual earnings per share (EPS)?

    Kura Oncology’s EPS for 12 months was -$2.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »